ANAB logo

AnaptysBio Inc. (ANAB)

$45.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANAB

Market cap

$1.36B

EPS

-1.02

P/E ratio

--

Price to sales

5.85

Dividend yield

--

Beta

0.378521

Price on ANAB

Previous close

$45.73

Today's open

$45.81

Day's range

$44.99 - $46.19

52 week range

$33.01 - $73.30

Profile about ANAB

CEO

Daniel Faga

Employees

104

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

29729847

Issue type

Common Stock

ANAB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ANAB

AnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 Transcript

AnaptysBio, Inc. ( ANAB ) UBS Global Biopharma Conference 2026 November 17, 2026 11:40 AM EST Company Participants Daniel Faga - President, CEO & Director Conference Call Participants Madeleine Lee - UBS Investment Bank, Research Division Presentation Madeleine Lee UBS Investment Bank, Research Division All right. So I think we'll get started with our last fireside of the day.

news source

Seeking Alpha • a day ago

news preview

Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 12, 2026

news preview

AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.52 per share a year ago.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Anaptys Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

news source

GlobeNewsWire • Nov 10, 2026

news preview

Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity

We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.

news source

Seeking Alpha • Oct 30, 2026

news preview

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.

news source

Seeking Alpha • Oct 29, 2026

news preview

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 27, 2026

news preview

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.

news source

GlobeNewsWire • Oct 19, 2026

news preview

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged by double digits.

news source

Investors Business Daily • Oct 12, 2026

news preview

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

news source

GlobeNewsWire • Sep 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in AnaptysBio Inc.

Open an M1 investment account to buy and sell AnaptysBio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANAB on M1